Ointment for treatment of autoimmune diseases

FIELD: medicine, rheumatology, pharmacy.

SUBSTANCE: invention proposes ointment as a curative agent that comprises the following components: 5-amino-2,3-dihydro-1,4-phthalazinedione alkaline salt of mixture of alkaline salts, medicinal vaseline, vaseline oil as an ointment base and distilled water taken in the following ratio of components, wt.-%: 5-amino-2,3-dihydro-1,4-phthalazinedione alkaline salt or 5-amino-2,3-dihydro-1,4-phthalazinedione mixture of alkaline salts, 1.0-50.0; medicinal vaseline, 10.0-20.0; vaseline oil, 5.0-10.0, and water, the balance, wherein 5-amino-2,3-dihydro-1,4-phthalazinedione sodium or potassium salt is used as an alkaline salt, and 5-amino-2,3-dihydro-1,4-phthalazinedione sodium and potassium salts mixture is used as mixture of alkaline salts composed of the equal ratio of components, i. e. 5-amino-2,3-dihydro-1,4-phthalazinedione sodium and potassium salts mixture. Indicated ointment normalizes membrane cell to the normal state damaged as result of disease, regulated intra- and intercellular metabolic processes that, in turn, promotes to normalization of metabolism and arresting inflammation for the shortest times. Invention can be used in treatment of autoimmune disease.

EFFECT: improved and valuable medicinal properties of ointment.

3 ex

 

The invention relates to medicine and can be used to treat diseases caused by immune response against its own tissues and organs.

Known external means local applications to reduce inflammation and pain relief in the treatment of rheumatoid arthritis, osteoarthritis deformans, arthropathy, etc. containing 10-50% aqueous or alcoholic solutions "Dimexidum (see, for example, Medmaravis. "Drugs". M: "Medicine", 1985, vol. 1, s-203). This tool is in the form of applications using soaked in the appropriate solution wipes daily put on the affected area for 20-30 minutes once a day for 10-15 days.

This tool is contraindicated in violation of antitoxic liver function and renal excretory function, angina, atherosclerosis, glaucoma and cataract, etc.

The closest analogue prototype is the ointment "Corticalization containing 0.5 g of hydrocortisone acetate, 0.2 g of chloramphenicol, 10 g of anhydrous lanolin, 22,5 g medical vaseline and vaseline oil and 100 g of other fillers and distilled water (see, for example, Medmaravis. "Drugs". M: "Medicine", 1985, vol. 1, s).

This ointment is used to treat inflammatory and allergic ill the of the skin, moreover, it is applied on the affected areas 2-3 times a day in a daily dose of from 2 to 30, However, the application of this ointment is contraindicated in tuberculosis, fungal and viral diseases of the skin, and when her ulcers.

The present invention solves the problem of obtaining ointment for the treatment of autoimmune diseases its implementation without limitation of its use by any contraindications.

The essence of the invention lies in the fact that the ointment for the treatment of autoimmune diseases containing the drug in ointment base, characterized by the fact that as a drug it includes alkaline salt or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione and ointment base is made in the form of medical vaseline and vaseline oil, and distilled water in the following ratio of components, wt.%: alkaline salt of 5-amino-2,3-dihydro-1,4-phthalazinedione or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 1,0-50,0; vaseline medical - 10,0-20,0; vaseline oil - 5,0-10,0; water - the rest, and as the alkaline salt used is sodium or potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione, and as a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione used is composed of, for example, with an equal ratio of components of the mixture sodium and the Aliyeva salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

Studies have shown that the bifurcation activity used drug in inflammatory processes selectively, for a few hours inhibits the activity of macrophages, reducing accordingly the level of TNF and ostrofsky proteins, which leads to smoothing of the symptoms of intoxication. When this happens enhanced superoxidedismutase function and phagocytic activity of neutrophils and the corresponding strengthening of microbicide system cells and the relief of the inflammatory process.

When weak response cellular immunity, for example, in the presence of malignant tumors of the proposed method of treatment due to the introduction of a medicinal product of an alkaline salt or mixture of alkali salts of 5-amino-2,3-dihydro-1,4-phthalazinedione provides the release of TNF (tumor necrosis factor, interleukins and other ostrofsky proteins, indicating that the activation of macrophages. At the same time as specifically react to the introduction of a drug T-lymphocytes.

Studies have shown that entered the patient the drug in the form of alkali (sodium or potassium) salt of 5-amino-2,3-dihydro-1,4-phthalazinedione (chemical formula accordingly - or8H6N3About2Na, or8H6N3About2 K) or mixtures of these alkaline salts of this salt (mixture of salts) is divided into metal cations (respectively Na+or K+) and anions 5-amino-3-hydro-1,4-phthalazinedione (respectively8H6N3About2-). However cations fill the needs of the body, and anions interacting, for example, blood plasma, disintegrate emitting carbon, atomic oxygen, nitrogen and hydroxyl group (OH). Then oxygen and nitrogen are recovered, thereby setting the antioxidant activity and hydroxyl groups interact with carbon, translating KHS from a state of acidosis in the alkaline side.

In addition, due to the presence of the chemiluminescent properties lyuminola on the basis of which formed the drug, under oxidative reactions with lyuminola (with the anion of 5-amino-3-hydro-1,4-phthalazinedione) is the emission of light energy (see also, for example, http://www.gpo.ucop.edu, Briheim et al., 1984), and in the interaction with albumin increased intensity of chemiluminescence proportional to the increase in the concentration of albumin (see ibid., Buturlakin et al., 1975).

Studies have shown that the emission of light energy by chemiluminescence is perceived by the cells of the body, and the emitted when the quanta of light energy are involved in the mechanism of exchange settings as contributing to the process of exchange of energy supply.

Studies have also shown that in the case of a changed state of the membrane (cytoplasm) of the cell (which is a consequence of many diseases) introduction drug alkali metal salts or mixtures of these salts lyuminola causes the membrane in the normal state, normalizes and regulates inside and intercellular metabolic processes and therefore normalizes metabolism.

The invention is confirmed by the examples.

Example 1.

Patient C., 52.

Diagnosis: rheumatoid arthritis.

After treatment, acute pain who assigned the lubrication of joints in a month, two times a day with an ointment containing a mixture (wt.%) taken in equal proportions of sodium and potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 50,0, as well as ointment base comprising liquid paraffin - 10,0, medical vaseline - 20,0; distilled water - the rest.

Further recommended preventive lubrication of the joints on the night ointment containing the potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 15,0, as well as ointment base comprising liquid paraffin - 10,0, medical vaseline - 20,0; distilled water - the rest.

Two control surveys every six months with complaints on pain in joints not.

Example 2.

Patient A., 62.

Admission: hemorrhagic rash on the neck under the chin and cha the hand on the chest (15 cm× 5 cm).

Diagnosis: systemic lupus erythematosus.

The treatment, which included daily, within one and a half months, 2 meals a day (morning and evening) lubrication affected areas ointment containing (in wt.%) taken in equal proportions of sodium and potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 50,0, as well as ointment base comprising liquid paraffin - 10,0, medical vaseline - 20,0; distilled water - the rest.

After the treatment zones rash pale, painless, tone raised.

Further recommended to continue treatment, including lubrication in the morning and in the ointment containing (in wt.%) sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 25,0, as well as ointment base comprising liquid paraffin - 10,0, medical vaseline - 20,0; distilled water - the rest, and at night - ointment containing (in wt.%) potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 15,0, as well as ointment base comprising liquid paraffin - 10,0, medical vaseline - 20,0; distilled water - the rest.

Six months after starting treatment zone rashes barely noticeable, the patient's condition is satisfactory.

Example 3.

Patient R., 79 years old.

Complaints of muscle pain in the shoulders and hips, the eruption of rashes on the surface of the brushes and the rear of the knees.

During examination: presence of rash, painful experienced what I palpation of the muscles, weak blue cheeks, swelling.

The diagnosis of dermatomyositis.

From the injection the patient refused for fear of introducing infection.

The treatment consisted of a daily 3 times a day, during the month of rubbing of the muscles of the shoulders and hips, and rash rash ointment, containing (wt.%) taken in equal proportions of potassium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 50,0, as well as ointment base comprising liquid paraffin - 10,0, medical vaseline - 20,0; distilled water - the rest.

After the treatment, the condition is satisfactory. In the future the patient is proposed to conduct routine before bed rubbing ointment containing (in wt.%) potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione to 5.0, as well as ointment base comprising liquid paraffin - 10,0, medical vaseline - 10,0; distilled water - the rest.

Ointment for the treatment of autoimmune diseases containing the drug in ointment base, characterized by the fact that as a medicine it includes alkaline salt or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione and ointment base is made in the form of medical vaseline and vaseline oil, and distilled water in the following ratio of components, wt %: alkaline salt of 5-amino-2,3-dihydro-1,4-phthalazinedione or mesh alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione from 1.0 to 50.0; vaseline medical 10,0-20,0; vaseline oil 5,0-10,0, water, rest, and as alkaline salts using sodium or potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, and as a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione use is made with equal proportions of the components of the mixture of sodium and potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.



 

Same patents:

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new 6-alkyl-5-(2-isonicotinoylsulfohydrazoyl)uracil hydrochlorides of the general formula (I) wherein R means alkyl comprising 1-4 carbon atom. Compounds possess an anti-mycobacterial and an immunotropic activity and can be used as an immunomodulating agent and an anti-mycobacterial agents. Also, invention relates to a pharmaceutical composition based on thereof.

EFFECT: valuable medicinal properties of compounds.

4 cl, 10 tbl, 2 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with cooling selected fertilized uninfected eggs at 2-4 C up to 7 d followed by homogenization, diluting with physiological solution of egg mass, bactericidal treatment, conservation with phenol solution up to its concentration being 0.3% at subsequent filtration of target product. Moreover, egg mass should be diluted with physiological solution at the ratio of 1:5, then comes thermal treatment upon water bath at 70-80 C for 1 h and before conservation one should cool the target product in bactericidal chamber under the lamp with ultraviolet irradiation for 30-40 min. The method provides increased total and specific body resistance, it enables to obtain cheaper and more acceptable biostimulant and simplified way for preparing.

EFFECT: higher efficiency.

4 ex, 3 tbl

FIELD: medicine, biopharmacology, immunology.

SUBSTANCE: invention relates to manufacturing curative-prophylactic preparations based on leukocyte interferon and natural cytokines. The preparation based on complex of natural cytokines is prepared by induction of human leukocytes with Newcastle disease virus of strain "H". Indicated complex of natural cytokines is prepared by at least two treatments of leukocytes before induction stage with virus with the same natural complex of cytokines prepared in previous stage of induction. Complex is purified from foreign proteins of inductor and comprises 104 IU of antiviral activity of human interferon-alpha in one ampoule, not less, and cellular cytokines, phosphate buffer for maintaining pH 6.9-7.5, sodium chloride and mannitol. The end product is lyophilized for preparing the injection preparation. Invention provides increasing activity of the preparation and to retain the natural complex of cytokines.

EFFECT: improved preparing method, valuable medicinal properties of preparation.

3 cl, 2 ex

FIELD: medicine, gastroenterology, pharmacy.

SUBSTANCE: invention relates to agents used in treatment of ulcerous-erosion injures in gastroduodenal region. Method involves diluting 100 mcg of dry lyophilized powder of immunomodulating agent "Superlimf" in 3-5 ml of 0.9% isotonic solution and irrigation of ulcer or erosion with this solution 1 time per a day by the endoscopy method. The treatment course is 3-4 procedures with break for 4-5 days. Method provides alteration of cytokine pattern of tissues, induction of influx of mononuclear phagocytes to the injure focus that results to localization of inflammation and the complete epithelization of ulcers and erosions.

EFFECT: improved and effective method for treatment.

1 ex

FIELD: medicine, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a method for preparing an anti-inflammatory, wound-healing, capillary-strengthening, immunomodulating agent. Method for preparing an anti-inflammatory, wound-healing, capillary-strengthening, immunomodulating agent is carried out for four stages. At the first stage violet tricolor and/or field milled herb is extracted with fluidized carbon dioxide under the definite condition followed by separation of grist from lipophilic fraction of extract; at the second stage defatted grist is subjected for three-fold extraction by remaceration method under the definite condition followed by treatment and purification of combined extract, treatment, condensation and preparing liquid alcoholic extract; at the third stage liquid alcoholic extract is used for preparing polysaccharide and flavonoid complexes by precipitation of polysaccharide with three-fold volume of 96% ethyl alcohol and the following drying at the definite temperature; at the forth stage grist after isolation of polysaccharide and flavonoid complexes is used for preparing pectins by treatment with three-fold volume of ammonium oxalate solution at the definite temperature, evaporation and drying. Liquid alcoholic is evaporated to 1/5 of the parent volume, dried by spraying drying or lyophilic drying at definite temperatures. Each end product prepared at each stage can be used as both independent medicinal formulation and can be used for preparing other medicinal formulations (tablets, capsules, suppositories, films). Also, invention relates to a method for preparing an anti-inflammatory, wound-healing, capillary-strengthening, immunomodulating agent that involves extraction of violet tricolor and/or field milled herb with 70% ethyl alcohol by infusion for a definite time followed by purification of the end product, settling at the definite temperature and filtration. Method provides preparing agent with broad pharmacological pattern of action and provides the maximal using the medicinal vegetable raw.

EFFECT: improved preparing method, valuable medicinal properties of agent.

5 cl, 5 tbl, 17 ex

FIELD: medicine.

SUBSTANCE: means has lipid fraction obtained from Berryteuthis Magister Comandor squid liver containing 10% of polyunsaturated fatty acids and 50% of alkyl-diacylglycerides showing marked lipid-correcting and immunomodulating properties.

EFFECT: enhanced effectiveness in treating lipid metabolism disorders and immunity system disorders.

4 tbl

FIELD: medicine.

SUBSTANCE: method involves administering inmmunotherapy with recombinant interferon-α2b in daily dose of 3x106 MU. It is incubated in thermostat during 1 h at 37°C with 100 ml of autoblood and then it is intravenously introduced to a patient during 1-1.5h daily under blood formula control to reach leukocyte content of>4*109 /l, granulocytes >2*109 /l.

EFFECT: eliminated leukopenia and dose-limiting toxicity risk; accelerated treatment course; reduced risk of infectious complications.

FIELD: agriculture, veterinary science.

SUBSTANCE: during the 1st d after forming raising groups one should once inject intramuscularly a solution of "Complex A" preparation at the dosage of 0.30-0.32 mg/kg body weight for 45-60-d-aged piglets and simultaneously with fodder one should introduce "Lactobifadol" preparation at the quantity of 0.50-0.52 g/kg body weight during the first 1-5 d. The present innovation enables to activate immune system, increase total protein and hemoglobin in blood that in its turn, prevents bronchopneumonia and remove stress in piglets after forming special raising groups.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: as an immunomodulating remedy one should introduce tamerite per 0.5 ml subconjunctivally and per 1.5 ml i/m daily for 5 d. The method provides normalization of immunity values due to additional local complex manifestation of immunomodulating, antiphlogistic, antioxidant and regenerating effects of tamerite.

EFFECT: higher efficiency of complex therapy.

2 ex

FIELD: food industry.

SUBSTANCE: invention relates to food additives that can be used to prevent immunodeficiency conditions. Immunomodulator is prepared via homogenization of lymphatic nodes in sodium chloride solution, autolysis, centrifugation, heating of supernatant to 80°C, cooling, removal of precipitate, and drying of supernatant by cooling it and placing it into atmospheric sublimation installation followed by subsequent post-drying using IR drying technique.

EFFECT: simplified immunomodulator preparation process and preserved biological and food values of finished product without creation of special temperature regime.

5 tbl, 2 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: as an immunomodulating remedy one should introduce tamerite per 0.5 ml subconjunctivally and per 1.5 ml i/m daily for 5 d. The method provides normalization of immunity values due to additional local complex manifestation of immunomodulating, antiphlogistic, antioxidant and regenerating effects of tamerite.

EFFECT: higher efficiency of complex therapy.

2 ex

FIELD: organic chemistry, medicine, gastroenterology, pharmacy.

SUBSTANCE: invention relates to a pyrrolopyridazine derivative of the following formula: wherein R1 represents (C3-C7)-cycloalkyl-(C1-C6)-alkyl group that can be substituted optionally with (C1-C6)-alkyl group; R2 represents (C1-C6)-alkyl group; R3 represents hydroxymethyl group, (C2-C6)-aliphatic acyloxymethyl group, (C6-C10)-arylcarbonyloxymethyl group, (C1-C6)-alkoxycarbonyloxymethyl group, formyl group, carboxyl group, (C1-C6)-alkoxycarbonyl group or (C6-C10)-aryloxycarbonyl group; R4 represents (C6-C10)-aryl group that can be substituted optionally with substitutes taken among the group consisting of (C1-C6)-alkyl groups, halogen-(C1-C6)-alkyl groups, (C1-C6)-alkoxy-groups, halogen-(C1-C6)-alkoxy-groups and halogen atoms; A represents imino-group, oxygen or sulfur atom, or its pharmaceutically acceptable salt. Pyrrolopyridazine derivatives elicit inhibitory activity with respect to gastric juice secretion and protective activity with respect to stomach mucosa and can be useful as a curative agent for prophylaxis or treatment of ulcer disease. Except for, invention relates to a pharmaceutical composition based on compounds of the invention and to a method for prophylaxis and treatment of ulcer disease.

EFFECT: valuable medicinal properties of compound.

25 cl, 1 tbl, 11 ex

The invention relates to the field of pharmaceutical industry and relates to pharmaceutical compositions for the treatment of herpes virus infection
Drug // 2238730
The invention relates to medicine, namely to medicines broad-spectrum

The invention relates to medicine, therapy, and can be used for treatment of pain

The invention relates to organic chemistry and can find application in medicine

The invention relates to 7-chloro-4-hydroxy-2(2-chloro-4-were)-1,2,5,10-tetrahydropyridine[4,5-b]quinoline-1,10-dione, its pharmaceutically acceptable salts, methods for treating pain, when administered pain relieving effective amount of this compound, and pharmaceutical compositions containing this compound

The invention relates to medicine, namely to medicines affecting the immune system, as well as chemical and pharmaceutical production of these medicines

The invention relates to a new inhibitor of serine proteases of the formula (I):

in which J is an R1, R1-SO2-, R3OOC-(CHR2)p- or (R2aR2b)N-CO-(CHR2)P-;D is an amino acid of formula-NH-CHR1-C(O) -, or-NR4-CH[(CH2)qC(O)OR1]-C(O)-; E is-NR2-CH2or fragment

R1selected from (1-12C)alkyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, groups which are optionally substituted (3-12C)cycloalkyl, and from (14-20C)(biaryl)alkyl; each of R2, R2Aand R2bindependently selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (6-14C)aryl; R3has the same values, which is defined for R2; R4represents H; X and Y are CH; m is 1 or 2; p is 1, 2 or 3; q is 1, 2 or 3; t is 2, 3 or 4; or N-alkoxycarbonyl-substituted derivative; and/or its pharmaceutically acceptable salt additive and/or MES

The invention relates to new physiologically active substituted oxazolo[4,5-d]pyridazine General formula (1), (2) or (3) and combinatorial library designed to search among them physiologically active substances, compounds leaders and candidates (drug-candidates) on the basis of screening

FIELD: organic chemistry, medicine, gastroenterology, pharmacy.

SUBSTANCE: invention relates to a pyrrolopyridazine derivative of the following formula: wherein R1 represents (C3-C7)-cycloalkyl-(C1-C6)-alkyl group that can be substituted optionally with (C1-C6)-alkyl group; R2 represents (C1-C6)-alkyl group; R3 represents hydroxymethyl group, (C2-C6)-aliphatic acyloxymethyl group, (C6-C10)-arylcarbonyloxymethyl group, (C1-C6)-alkoxycarbonyloxymethyl group, formyl group, carboxyl group, (C1-C6)-alkoxycarbonyl group or (C6-C10)-aryloxycarbonyl group; R4 represents (C6-C10)-aryl group that can be substituted optionally with substitutes taken among the group consisting of (C1-C6)-alkyl groups, halogen-(C1-C6)-alkyl groups, (C1-C6)-alkoxy-groups, halogen-(C1-C6)-alkoxy-groups and halogen atoms; A represents imino-group, oxygen or sulfur atom, or its pharmaceutically acceptable salt. Pyrrolopyridazine derivatives elicit inhibitory activity with respect to gastric juice secretion and protective activity with respect to stomach mucosa and can be useful as a curative agent for prophylaxis or treatment of ulcer disease. Except for, invention relates to a pharmaceutical composition based on compounds of the invention and to a method for prophylaxis and treatment of ulcer disease.

EFFECT: valuable medicinal properties of compound.

25 cl, 1 tbl, 11 ex

Up!